TY - JOUR
T1 - Disease behaviour classification
T2 - a pragmatic model for predicting outcomes in interstitial lung disease
AU - Harrison, Megan
AU - Jo, Helen E.
AU - Troy, Lauren K.
AU - Nguyen, Benjamin
AU - Webster, Susanne E.
AU - Geis, Monika
AU - Lai, Simon
AU - Mulyadi, Ellie
AU - Cooper, Wendy A.
AU - Mahar, Annabelle
AU - Teoh, Alan
AU - Jee, Adelle
AU - Corte, Tamera J.
PY - 2024/4
Y1 - 2024/4
N2 - Background and objective: The interstitial lung diseases (ILD) are a heterogenous group of disorders with similar clinical presentation, but widely varying prognoses. The use of a pragmatic disease behaviour classification (DBC), first proposed in international guidelines in 2013, categorises diseases into five behavioural classes based on their predicted clinical course. This study aimed to determine the prognostic utility of the DBC in an ILD cohort. Methods: Consecutive patients presented at the weekly multidisciplinary meeting (MDM) of a specialist ILD centre were included. MDM consensus was obtained for diagnosis and DBC category (1–5). Baseline and serial clinical and physiological data were collected over the study period (median 3.9 years, range 0–5.4 years). The relationship between DBC and prognostic outcomes was explored. Results: 137 ILD patients, [64 (47%) female] were included with mean age 67.0 ± 1.1 years, baseline FVC% 72.7 ± 1.7, and baseline DLco% 57.8 ± 1.6%. Patients were stratified into DBC by consensus at MDM: DBC1 n = 0 (0%), DBC2 n = 16 (12%), DBC3 n = 10 (7.3%), DBC4 n = 55 (40%), and DBC5 n = 56 (41%). On univariable Cox regression, increasing DBC class was associated with poorer progression-free survival (HR 1.6, 95% CI 1.2–2.0, p < 0.001). On multivariable Cox regression, DBC remained predictive of PFS when combined with age and gender (HR 1.4, 95% CI 1.1–1.9, p = 0.011), baseline FVC% (HR 1.5, 95% CI 1.1–1.8, p = 0.003) and ILD diagnosis (HR 1.6, 95% CI 1.2–2.2, p < 0.0001). Conclusion: DBC as determined at ILD multidisciplinary meeting may be a useful prognostic tool for the management of ILD patients.
AB - Background and objective: The interstitial lung diseases (ILD) are a heterogenous group of disorders with similar clinical presentation, but widely varying prognoses. The use of a pragmatic disease behaviour classification (DBC), first proposed in international guidelines in 2013, categorises diseases into five behavioural classes based on their predicted clinical course. This study aimed to determine the prognostic utility of the DBC in an ILD cohort. Methods: Consecutive patients presented at the weekly multidisciplinary meeting (MDM) of a specialist ILD centre were included. MDM consensus was obtained for diagnosis and DBC category (1–5). Baseline and serial clinical and physiological data were collected over the study period (median 3.9 years, range 0–5.4 years). The relationship between DBC and prognostic outcomes was explored. Results: 137 ILD patients, [64 (47%) female] were included with mean age 67.0 ± 1.1 years, baseline FVC% 72.7 ± 1.7, and baseline DLco% 57.8 ± 1.6%. Patients were stratified into DBC by consensus at MDM: DBC1 n = 0 (0%), DBC2 n = 16 (12%), DBC3 n = 10 (7.3%), DBC4 n = 55 (40%), and DBC5 n = 56 (41%). On univariable Cox regression, increasing DBC class was associated with poorer progression-free survival (HR 1.6, 95% CI 1.2–2.0, p < 0.001). On multivariable Cox regression, DBC remained predictive of PFS when combined with age and gender (HR 1.4, 95% CI 1.1–1.9, p = 0.011), baseline FVC% (HR 1.5, 95% CI 1.1–1.8, p = 0.003) and ILD diagnosis (HR 1.6, 95% CI 1.2–2.2, p < 0.0001). Conclusion: DBC as determined at ILD multidisciplinary meeting may be a useful prognostic tool for the management of ILD patients.
KW - Classification
KW - Interstitial
KW - Lung diseases
KW - Prognosis
KW - Pulmonary fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85185438226&partnerID=8YFLogxK
UR - https://go.openathens.net/redirector/westernsydney.edu.au?url=https://doi.org/10.1016/j.rmed.2024.107533
U2 - 10.1016/j.rmed.2024.107533
DO - 10.1016/j.rmed.2024.107533
M3 - Article
C2 - 38355019
AN - SCOPUS:85185438226
SN - 0954-6111
VL - 224
JO - Respiratory Medicine
JF - Respiratory Medicine
M1 - 107533
ER -